semaglutide and heart disease GLP-1 Agonists in Cardiovascular Diseases: Mechanisms, Clinical Evidence, Emerging Therapies Semaglutide may reduce heart events

Analytical runs were performed at a flow rate of 0.5 mL/min with gradient elution of 1070 % B using 0.05% trifluoroacetic acid in water (A) and 0.05% trifluoroacetic acid in acetonitrile (B)

This is its primary mechanism for weight loss

9 The consensus statement from the American Association of Clinical Endocrinologists supports the use of GLP-1 RAs as first-line therapy in managing hyperglycaemia in T2D patients with established (or at high risk of) atherosclerotic CVD, as well as in those with chronic kidney disease or a history of stroke or transient ischaemic attack, while recommending the administration of sodiumglucose cotransporter 2 inhibitors to HF patients

The medication slows her digestion to the point where she feels perpetually full, making it hard to consume enough food throughout the day